ABSTRACT -An important technology used in toxicogenomic drug discovery research is the microarray, which enables researchers to simultaneously analyze the expression of a large number of genes. To build a database and data analysis system for use in assessing the safety of drugs and drug candidates, in 2002 we conducted a 5-year collaborative study in the Toxicogenomics Project (TGP1) in Japan. Experimental data generated by such studies must be validated by different laboratories for robust and accurate analysis. For this purpose, we conducted intra-and inter-laboratory validation studies with participating companies in the second collaborative study in the Toxicogenomics Project (TGP2). Gene expression in the liver of rats treated with acetaminophen (APAP) was independently examined by the participating companies using Affymetrix GeneChip microarrays. The intra-and inter-laboratory reproducibility of the data was evaluated using hierarchical clustering analysis. The toxicogenomics results were highly reproducible, indicating that the gene expression data generated in our TGP1 project is reliable and compatible with the data generated by the participating laboratories.
INTRODUCTION
Toxicogenomic and pharmacogenomic methodologies are playing increasingly important roles in drug discovery research. One of the key technologies used in toxicogenomic and pharmacogenomic studies is the microarray, which permits the simultaneous analysis of the expression of a large number of genes. The National Institute of Health Sciences, and the National Institute of Biomedical Innovation, and Japanese pharmaceutical companies began a 5-year collaborative study in the Toxicogenomics Project (TGP1) in Japan from 2002 Takashima et al., 2006) . The aim of TGP1 was to construct a large-scale database for use in predicting the toxicity of new molecular entities during the early stages of drug development. In TGP1, gene expression profiles were generated for the liver, kidney, and primary hepatocytes of rats, and for human primary hepatocytes treated with 150 different chemicals, including various drugs and typical toxicants. These gene expression profile data, integrated with data regarding histopathological changes, the results of blood biochemical examinations, and other phenotypic profiles, are stored in the TG-GATEs (Genomics Assisted Toxicity Evaluation System), which was developed by the Toxicogenomics Project in Japan. After completion of TGP1, the second 5-year collaborative Toxicogenomics Project (TGP2) was begun in 2007. The purpose of TGP2 was to identify biomarkers for diagnosing and/or predicting compound toxicity based upon the gene expression data accumulated in TGP1. A number of biomarkers and gene expression profiles indicative of exposure to particular toxic compounds were reported following the TGP1 and TGP2 studies (Kiyosawa et al., 2006; Morishita et al., 2006; Tamura et al., 2006a Tamura et al., , 2006b Kiyosawa et al., 2007; Omura et al., 2007; Hirode et al., 2008 Hirode et al., , 2009a Hirode et al., and 2009b Uehara et al., 2008a Uehara et al., , 2008b Uehara et al., and 2008c Kondo et al., 2009; Minowa et al., 2012) . Prior to use of the gene expression data accumulated during TGP1 in future drug discovery studies, the procedures used to analyze gene expression must be validated and the degree of inter-laboratory variation must be assessed. Many studies, including the MicroArray Quality Control (MAQC) project (Liang, 2007; Pan, 2002; Patterson et al., 2006; Shi et al., 2006) , have been performed to assess the reproducibility of gene expression profiling data across laboratories and platforms. Results from the MAQC project showed that microarray data are highly reproducible and that the criteria used to define whether a gene is differentially expressed play a role in the overlap of resulting gene lists. Though the technical performance and reproducibility of the microarray results were clearly described by Shi et al. (2006) using the two RNA samples, Stratagene Universal Human Reference RNA and Ambion Human Brain Reference RNA1, which are not biologically related, the authors of that study did not address whether microarray data generated through analysis of their samples by different laboratories or platforms would result in the same biological interpretation of the results. Evaluating a biologically relevant toxicogenomics data set generated using RNA samples from rats treated with aristolochic acid, riddelliine, and comfrey, Guo et al. (2006) reported that there was a high degree of concordance between interlaboratory and cross-platform comparisons of the data.
Here, we validated gene expression data generated by the 12 laboratories participating in the TGP2 study. We found that the inter-laboratory reproducibility of our biologically relevant toxicogenomics data set was high.
MATERIALS AND METHODS

Animal Treatment
The animal experiments were carried out as described before (Takashima et al., 2005) . The study used 6-weekold male Crl:CD(SD) rats (Charles River Japan Inc., Kanagawa, Japan), which were housed individually in stainless-steel cages with a 12-hr photoperiod and allowed free access to water and pellet diet (CRF-1, sterilized by radiation, Oriental Yeast Co., Ltd., Tokyo, Japan). Acetaminophen (Sigma-Aldrich, Tokyo, Japan) was suspended in a 0.5% (w/v) methylcellulose (MC) solution and administered orally by gavage at a dose of 0 (vehicle control), 300 (low dose), or 1,000 (high dose) mg/kg to 5 rats in each dose group. Animals were euthanized 24 hr after dosing by exsanguination under ether anesthesia. Samples of liver for use in RNA analyses were collected immediately after sacrifice and soaked and kept in RNAlater (Ambion, Austin, TX, USA) until used.
Liver samples for use in histopathological examinations were fixed in 10% neutral buffered formalin, dehydrated in alcohol, then embedded in paraffin. Paraffin sections were prepared and stained using a routine hematoxylin and eosin (H&E) method. Blood chemistry and hematological parameters were measured according to the procedures of contract research organization (CRO) procedures. The experimental protocols were reviewed and approved by the Ethics Review Committee for Animal Experimentation of the National Institute of Biomedical Innovation.
Microarray analysis
Liver samples were obtained independently from the 5 rats in each dose group, kept in RNAlater, and then homogenized in Buffer RLT (Qiagen, Valencia, CA, USA). Homogenizing was performed by adding a 5 mm diameter Zirconium bead (Funakoshi, Tokyo, Japan) and shaking with a MixerMill 300 (Qiagen GmbH., Hilden, Germany) at a speed of 20 Hz for 5 min. Homogenized samples were dispensed into tubes for distribution to the participating laboratories. One out of the five samples from each dose group (rats designated as V1, L1, and H1) was assayed in triplicate in order to assess the experimental error associated with each laboratory. Subsequent procedures were performed independently in the TGP2 laboratory and in the laboratories of the 11 participating Japanese pharmaceutical companies. In each laboratories, total RNA was isolated and purified from liver homogenate using and an RNeasy Mini Kit (Qiagen, Valencia, CA, USA), generally according to the manufacturer's instructions. Gene expression profiles were determined using One-Cycle Target Labeling and Control Reagents and GeneChip Rat Genome 230 2.0 arrays (Affymetrix, Santa Clara, CA, USA), generally according to the manufacturer's instructions. The resulting digital image files were preprocessed using Affymetrix Microarray Suite software, version 5.0 (MAS5.0), and each sample was normalized by dividing its value by the mean value for all genes, excluding the AFFX control probe sets. The data shown as sets A and B were measured in the TGP2 laboratory. The difference between sets A and B was only that samples in set A were externally added spike RNA derived from Bacillus subtilis for normalization (Kanno et al., 2006) . The data in sets C, D, E, G, H, I, J, and M were collected at 7 of the pharmaceutical companies using the same method used in set B at the TGP2 laboratory, whose differences between Affymetrix's instructions were the amount of starting total RNA (5 μg in TGP2, 1 μg in Affymetrix's) and the time of hybridization to GeneChip (18 hr in TGP2, 16 hr in Affymetrix's). Sets F and L were collected at 2 companies following the manufacturer's instructions for a method similar to that used by the TGP2 laboratory. In set F, total RNA was extracted only by an RNeasy Mini Kit, without TRIzol LS reagent (Life Technologies, Carlsbad, CA, USA) and DNase was not treated. In set L, at the total RNA extraction, TRIzol reagent (Life Technologies) was used instead of TRIzol LS reagent. Two methods were used at one company: the TGP2 method (set K) and a method generally following the manufacturer's instructions (set N). In set N, total RNA was extracted using QIAzol (Qiagen) and chloroform. In set F and N, the time of hybridization to GeneChip was 16 hr. A total of 14 data sets (sets A-N) were generated in this study.
Data analysis
We analyzed the reproducibility of the data using 2 gene list sets, the "all set" and "present set", which consisted of all 31,042 probe sets (excluding AFFX control probe sets) on the GeneChip Rat Genome 230 2.0 arrays and 10,210 probe sets showing a "present call" flag in all the data sets, respectively. For the analysis of the reproducibility, hierarchical clustering was performed using the "present set" gene list sets, Ward's algorithm, and Euclidean distance as the distance metric. A total of 6 different gene selection methods were used to determine the inter-laboratory overlap of the differentially expressed gene lists: (i) weighted average difference (WAD) rank ordering (Kadota et al., 2008) , (ii) significance analysis of microarrays (SAM) rank ordering (Tusher et al., 2001) , (iii) intensity-based moderated t-statistic (IBMT) rank ordering (Sartor et al., 2006) , (iv) Welch's t-test P-value rank ordering, (v) fold-change (FC) rank ordering, and (vi) random ranking. The percent overlap between the differentially expressed gene lists was then calculated.
RESULTS
Gene expression data were validated using liver samples obtained from rats from each of the 3 dose groups. The expression of genes in the liver of each of the 5 biological replicates in each treatment group was assayed independently, and 1 sample from each dose group was assayed in triplicate to assess the experimental error associated with each laboratory. Histopathological findings are shown in Supplementary Table 1. Cellular infiltration at centrilobular zone was observed in samples from the high-dose group. In contrast, no abnormal histopathological findings were noted in samples from low-dose group rats.
Analysis of the reproducibility by hierarchical clustering and Pearson's correlation
Hierarchical clustering analysis was used to assess the overall reproducibility of the microarray data generated by the 12 laboratories (Fig. 1) . Experimental replicate data obtained from V1, L1, and H1 individuals clustered together, except for the cluster from sets A and B. All the high-dose group samples formed one large cluster, without exception. Data from the different laboratories pertaining to the same individual sample also clustered together, except for the data from sets E and L. Although samples from the control and low-dose groups tended to cluster with the data generated by each laboratory for the same dose and same individual, the data for the control and low-dose groups formed clusters according to each data set in sets E, F, J, and L. The cluster consisting of data for the control and low-dose group samples in sets E and L was apart from the cluster consisting of data for the control and low-dose group samples in the other sets.
We also assessed the intra-and inter-laboratory reproducibility of the microarray data using Pearson's correlation analysis. Concerning the intra-laboratory reproducibility, the average correlation coefficient for the triplicate experimental data obtained from V1, L1, and H1 individuals at each laboratory was > 0.996 (Table 1) . With respect to individual differences, the average correlation coefficient for the data generated from the 5 individuals in each dose group at each laboratory was > 0.986 (Table 2) . Concerning the inter-laboratory reproducibility, the average correlation coefficient for the average data for a given dose group determined at one laboratory and the 13 data sets for the same dose group determined at the other laboratories was over 0.991, as shown in Table 3 . In all three cases, use of the "all set" or the "present set" made little difference.
Number of up/ down-regulated genes by Welch's t-test and FC
The number of genes that were either upregulated or downregulated was extracted from the "all set' data using Welch's t-test and FC rank ordering (Table 4a ). The most severe condition, with a P-value threshold of < 0.01 and a FC threshold of +2.0 indicated that approximately 140 genes were downregulated in the liver of rats from the high-dose group compared to the control group, while 240 genes were upregulated in the liver of rats from the highdose group. The number of upregulated and downregulated genes extracted using Welch's t-test and FC rank ordering with "present set" data is shown in Table 4b . The most severe condition, with a P-value threshold of < 0.01 and a FC threshold of +2.0, indicated that about 40 genes were downregulated and 110 genes were upregulated in the liver of rats from the high-dose group compared to the control group.
Inter-laboratory overlap of differentially expressed gene lists generated using different selection methods
The inter-laboratory concordance between lists of differentially expressed genes generated using different selection methods is shown in Fig. 2 . The number of overlaps between lists generated by 2 different laboratories with respect to genes that are differentially expressed in the liver of rats from the high-dose group (Fig. 2d) was greater than the number of overlaps for the low-dose group (Fig. 2c) . Moreover, the number of overlaps in lists prepared using "present set" data was greater than the number of overlaps in lists prepared using "all set" data, no matter which selection method was used to determine the degree of overlap. In particular, their difference was large when using FC rank ordering. The greatest number of overlaps was observed when WAD rank ordering was used as a selection method.
DISCUSSION
In TGP1, we constructed a large-scale rat toxicogenomics database with gene expression data derived from exposure of rats to over 150 chemicals. Before sharing the gene expression profiles generated in TGP1 with collaborators, the experimental data needed to be validated by different laboratories. For this purpose, we performed a large-scale inter-laboratory validation study This validation study has characterized the participation of 11 Japanese pharmaceutical companies. Livers of rats administered two doses of APAP served as a biologically relevant sample material for this study. As shown in Supplementary Table 1, pathological findings indicate that a high dose of APAP (1,000 mg/kg) was sufficient to produce toxicity in rats. In contrast, no histopathological signs of toxicity were observed in rats administered a low dose of APAP (300 mg/kg).
We first assessed the overall reproducibility of the 14 sets of microarray data generated by the 12 participating laboratories (including the TGP2 laboratory) using hierarchical clustering analysis (Fig. 1) . Intra-laboratory reproducibility was assessed by analyzing 1 out of each of the 5 samples in each dose group in experimentally triplicate. The experimental triplicate data for individuals V1, L1, and H1 clustered together, except for the data for individuals from sets A and B. Sets A and B were analyzed in the same laboratory, and their only difference was that 5 different external RNAs derived from Bacillus subtilis were added to samples from one set for the purpose of normalizing the data. The external RNAs had no effect on the gene expression analysis. With respect to inter-laboratory reproducibility, we found that data generated by the 12 participating laboratories for samples from the high-dose group clustered together without exception, and that data for samples from the same individual tended to form sub-clusters within the high-dose group cluster. This result showed that toxicity associated with exposure to high doses of APAP can be confidently distinguished through analysis of the liver gene expression profile. Although the data for the control and low-dose group samples tended to cluster by dose group and individual within the group, the data for the control and low-dose group samples clustered by data set in sets E, F, J, and L. These results suggested that InterͲlaboratory concordance (%)
Number of genes selected as differentially expressed a) low dose, "all set" c) low dose, "present set" b) high dose, "all set" d) high dose, " present set " Fig. 2 . Inter-laboratory overlap in lists of differentially expressed genes generated using different selection criteria. Genes differentially expressed in the liver of rats from the control and APAP treatment groups were identified and sorted at each laboratory using different gene selection criteria. In this analysis, top x ranked genes were defined as differentially expressed. The percent of genes identified as differentially expressed by 2 laboratories was calculated. The overlap between sets A and C are represented in the figure. The percent overlap in the lists generated by the other laboratories was the same as the percent overlap between sets A and C (data not shown). The x-axis represents the number of genes defined as differentially expressed in this analysis. The y-axis represents the overlap (%) between two gene lists for a given number of differentially expressed genes. Lines on the graph represent the inter-laboratory overlap between lists of differentially expressed genes generated using 5 different gene ranking/selection methods and random ranking/selection. the measurement error in each GeneChip system was less than or comparable to the differences between individuals in the same group. The cluster formed by the data for the high-dose group in sets E and L was separate from the cluster of data for the high-dose individuals in the other sets. It is possible that this may have been due to lowintensity signals unique to each GeneChip system used to analyze samples in sets E and L. We also assessed the intra-and inter-laboratory reproducibility of the microarray data using Pearson's corre- The table shows the average and standard deviation (S.D.) of the correlation coefficient for triplicate experimental data obtained from V1, L1, and H1 individuals at each laboratory using the "all set" (a) or "present set" (b).
lation analysis. The intra-laboratory reproducibility with respect to the results for the 3 experimental replicates and with respect to differences between the individuals within the same dose group was high (Tables 1 and 2 ). Correlation coefficient data indicated that the inter-laboratory reproducibility was also high (Table 3) . Next, we extracted the genes that were upregulated or downregulated based on 4 sets of criteria using Welch's t-test and FC rank ordering, which are the traditional methods for selecting differentially expressed genes The average and standard deviation (S.D.) of the correlation coefficient for data generated from the 5 individuals in each group at each laboratory using the "all set" (a) and "present set" (b).
( Table 4) . With sets E, F, J, and L, in which the data for the control and low-dose group samples formed clusters according to each data set, the number of genes extracted did not differ from the number extracted from the other sets (Table 4b) . We also assessed the inter-laboratory overlap in lists of differentially expressed genes generated using 5 different selection methods, as shown in Fig. 2 . In addition to The table shows the average and standard deviation (S.D.) of the correlation coefficient for gene expression data for a particular dose group determined by one laboratory and compared to the data for the same dose group in the other 13 data sets. (a) gene lists prepared using the "all set" and (b) gene lists prepared using the "present set" gene probe sets. Table 4 . Number of upregulated and downregulated genes determined using Welch's t-test and fold-change rank ordering a) "all set" The number of upregulated and downregulated genes determined using Welch's t-test or fold-change rank ordering is shown for the low-dose and high-dose treatments in each set. (a) and (b) show the number of differentially expressed genes determined using the "all set" and "present set" gene probe sets, respectively.
the standard Welch's t-test, the SAM (Tusher et al., 2001) and IBMT (Sartor et al., 2006) statistical tests have been used to identify differentially expressed genes. Use of the FC and WAD (Kadota et al., 2008) methods represents an alternative strategy for the identification of differentially expressed genes. The WAD rank ordering method is based upon fold change and is weighted according to signal intensity. The overlap in lists of the top 100 differentially expressed genes generated using WAD rank ordering was over 80%, and for lists generated using FC rank ordering the overlap was over 65% for samples from the highdose group using the "present set" (Fig. 2d) . There was significantly less overlap in lists generated using t-statistic criteria (SAM, IBMT, and Welch's t-test) compared to lists generated using WAD and FC (Fig. 2d ). This may be explained by the fact that t-statistic P-value calculations incorporate the influence of the signal-to noise ratio, which would tend to make gene selection methods based on fold-change more reproducible. Our results are consistent with those of Guo et al. (2006) , who demonstrated that a lower percentage of overlap is observed when the P-value is used as the criterion for gene ranking and selection than is observed when genes are selected based on a fold-change criterion. Comparing the data from each laboratory generated using the "all set" (Figs. 2a and 2b ) and "present set" lists ( Figs. 2c and 2d ), both at low dose (Figs. 2a and 2c) and at high dose (Figs. 2b and 2d) , there was more inter-laboratory agreement in the "present set" lists generated using FC rank ordering than with "all set" lists. This was considered to be due to the level of noise in the "all set" gene expression data. Although WAD was the gene selection method based on fold change, the interlaboratory concordance in lists of genes extracted using WAD (red) was much higher than that in lists generated using FC (purple) in the "all set" (Fig. 2b) . It was thought that this result was due to decreasing false selection by the noise level signals, because the expression changes of the genes showing low intensities in WAD was evaluated less than in FC. When top x ranked genes were used as criteria determining differentially expressed genes, at least, WAD was more proper than the other selection methods. These results suggested that selecting the proper method for generating lists of differentially expressed genes on each analysis is important for ensuring that microarray results are reproducible. GeneChip technology is a powerful tool for use in identifying differentially expressed genes. The technology can be applied to biomarker identification, elucidation of molecular mechanisms, and classification of samples based on gene expression profiles. The results of the present study will ensure the intra-and inter-laboratory reproducibility of microarray data generated by laboratories with sufficient expertise.
